Round 1
First sight of Dechert's Diane Sullivan, representing AZ!
Remember her from The Vioxx Trials?
The parallels with Vioxx are remarkable.
AstraZeneca's strategy is similar to Merck's tack for its former pain drug Vioxx. Merck pulled Vioxx from the market in 2004 after a clinical study showed it raised the risk of heart attacks and strokes. Despite such data, Merck essentially argued in court that it was impossible to prove that an individual's heart attack was caused by Vioxx use, and that the heart attacks could have been due to other risk factors. Merck won more jury verdicts than it lost before reaching a $4.85 billion settlement of most Vioxx suits in 2007.
WSJ
No comments:
Post a Comment